{
  "ticker": "JNJ",
  "date": "2026-01-05",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T12:03:30.078383",
  "source": "alpha_vantage",
  "article_count": 50,
  "articles": [
    {
      "title": "Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms",
      "summary": "Legend Biotech (LEGN) shares fell 4.7% to a new 52-week low of $20.49, ahead of CEO Ying Huang's presentation at the annual J.P. Morgan Healthcare Conference on January 14. This decline occurred as the broader biotech sector also experienced a downturn. Investors are closely watching for updates on CARVYKTI, Legend's key cancer therapy, focusing on patient access, manufacturing, and demand trends for 2026.",
      "url": "https://ts2.tech/en/legend-biotech-stock-hits-a-fresh-52-week-low-as-biotech-lags-jpmorgan-update-looms/",
      "source": "ts2.tech",
      "published": "20260105T211014",
      "overall_sentiment_score": -0.103115,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.134466,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.625688
    },
    {
      "title": "2,400 Stocks or 315 Value Picks: Is SCHB or VTV a Better Fit for Your Portfolio?",
      "summary": "This article compares two ETFs, SCHB and VTV, to help investors decide which is a better fit for their portfolio. SCHB offers broad market coverage of over 2,400 U.S. stocks with a tech bias, while VTV focuses on about 315 large-cap value stocks, primarily in financials and healthcare, and offers a higher dividend yield. The choice depends on investment goals, with SCHB appealing to those seeking full market representation and VTV",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/BRK-B-N/pressreleases/36877015/2400-stocks-or-315-value-picks-is-schb-or-vtv-a-better-fit-for-your-portfolio/",
      "source": "The Globe and Mail",
      "published": "20260105T161018",
      "overall_sentiment_score": 0.166969,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.149628,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.568563
    },
    {
      "title": "Rosacea Market Research and Forecast Report 2025-2035: Galderma, AbbVie, Bausch Health, Journey Medical, and Sol-Gel Drive Innovation Through Expanded R&D and Clinical Trials - ResearchAndMarkets.com",
      "summary": "The global rosacea market is projected for significant growth between 2025 and 2035, driven by increasing prevalence, regulatory approvals of new therapies, and the adoption of teledermatology. Despite challenges like high medication costs and underdiagnosis in diverse skin tones, key players such as Galderma, AbbVie, and Bausch Health are investing in R&D and strategic collaborations to develop advanced, patient-centric treatments. Emerging opportunities include targeted therapies, expansion into Asia-Pacific and Latin America, and a growing demand for sustainable skincare formulations.",
      "url": "https://aijourn.com/rosacea-market-research-and-forecast-report-2025-2035-galderma-abbvie-bausch-health-journey-medical-and-sol-gel-drive-innovation-through-expanded-rd-and-clinical-trials-researchandmarkets-com/",
      "source": "The AI Journal",
      "published": "20260105T141940",
      "overall_sentiment_score": 0.293505,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.213043,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.678389
    },
    {
      "title": "J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark",
      "summary": "Johnson & Johnson has halted a Phase IIb trial for JNJ-95475939, a bispecific antibody for atopic dermatitis, after it failed to meet efficacy expectations in an interim analysis. J&J had paid Numab Therapeutics $1.25 billion upfront for the asset, which targeted IL-4 and IL-31. The company will now focus on other dermatology candidates, including assets acquired from Proteologix and a STAT6 program from Kaken Pharmaceutical.",
      "url": "https://www.biospace.com/drug-development/j-j-stops-mid-stage-eczema-trial-as-1-25b-asset-misses-efficacy-mark",
      "source": "BioSpace",
      "published": "20260105T132726",
      "overall_sentiment_score": -0.606387,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment_score": -0.621428,
      "ticker_sentiment_label": "Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Experimental polycythemia vera drug could cut constant blood draws",
      "summary": "Takeda and Protagonist Therapeutics have submitted a New Drug Application (NDA) to the FDA for rusfertide, an investigational drug for polycythemia vera (PV). Rusfertide, a first-in-class hepcidin mimetic, aims to regulate red blood cell production and control hematocrit levels, potentially reducing the need for frequent phlebotomies in PV patients. This submission follows positive results from the Phase 3 VERIFY study, which demonstrated the drug's efficacy in maintaining hematocrit control and improving patient-reported outcomes.",
      "url": "https://www.stocktitan.net/news/TAK/takeda-and-protagonist-announce-submission-of-new-drug-application-t3ns0g4jslcz.html",
      "source": "Stock Titan",
      "published": "20260105T120938",
      "overall_sentiment_score": 0.322156,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.121869,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.612376
    },
    {
      "title": "Johnson & Johnson (JNJ) Valuation Check After Strong 1 Year Return And Ongoing Litigation Risks",
      "summary": "Johnson & Johnson (JNJ) stock has seen a significant 48.8% total shareholder return over the past year. Despite a perceived fair value closer to $360 and a consensus analyst target of $177.468, Simply Wall St assesses J&J's fair value at $209.29, suggesting it is currently undervalued even considering ongoing talc litigation risks and potential revenue impact from drug exclusivity losses. Investors can build custom narratives based on their assumptions using Simply Wall St's tools.",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-johnson-jnj-valuation-check-after-strong-1-year-retu",
      "source": "Simply Wall Street",
      "published": "20260105T103516",
      "overall_sentiment_score": 0.020781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.011477,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.305982
    },
    {
      "title": "Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting",
      "summary": "Protagonist Therapeutics announced upcoming oral and poster presentations focusing on clinical data for rusfertide in polycythemia vera at the 67th Annual American Society of Hematology (ASH) Meeting. Four presentations, including results from the Phase 3 VERIFY study and the Phase 2 THRIVE Extension Study, will cover durability of response, safety, patient-reported outcomes, and observations prior to rusfertide exposure. The company also provided an update on its broader pipeline, including icotrokinra and other preclinical programs.",
      "url": "https://www.vvdailypress.com/press-release/story/10381/protagonist-therapeutics-announces-oral-and-poster-presentations-on-rusfertide-at-the-67th-annual-ash-meeting/",
      "source": "Victorville Daily Press",
      "published": "20260105T081127",
      "overall_sentiment_score": 0.307126,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.211673,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.710133
    },
    {
      "title": "The Truth About Medtronic plc: Is This ‘Boring’ Stock Actually a Silent Flex?",
      "summary": "Medtronic plc is presented as a medical technology giant that, while not a \"meme stock,\" is a significant player in healthcare. The article explores whether this \"boring\" stock is a valuable long-term investment, examining its business, market perception, and risks. It concludes that Medtronic is a stable, dividend-paying company suited for core portfolios rather than speculative, high-volatility trading.",
      "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-medtronic-plc-is-this-boring-stock-actually-a/68460446",
      "source": "AD HOC NEWS",
      "published": "20260105T080832",
      "overall_sentiment_score": 0.178055,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.126265,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.618502
    },
    {
      "title": "Biotech developing organ transplant tech steps onto J.P. Morgan stage",
      "summary": "United Therapeutics Corporation announced that its CEO, Dr. Martine Rothblatt, will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a publicly-traded public benefit corporation, focuses on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.",
      "url": "https://www.stocktitan.net/news/UTHR/united-therapeutics-corporation-to-present-at-the-44th-annual-j-p-gl78b5l5rlhw.html",
      "source": "Stock Titan",
      "published": "20260105T070000",
      "overall_sentiment_score": 0.152256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.108678,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.558422
    },
    {
      "title": "Minnesota jury awards US$65.5 million verdict against Johnson & Johnson in talc asbestos case",
      "summary": "A Minnesota jury has awarded US$65.5 million in damages against Johnson & Johnson, finding its talc-based products exposed a plaintiff to asbestos, causing mesothelioma. The verdict, which covers compensatory losses, adds to the growing legal and financial pressure on the company over ongoing talc-related litigation. This is reportedly the largest asbestos-related award in Minnesota's history.",
      "url": "https://www.globalcosmeticsnews.com/minnesota-jury-awards-us65-5-million-verdict-against-johnson-johnson-in-talc-asbestos-case/",
      "source": "Global Cosmetics News",
      "published": "20260105T060424",
      "overall_sentiment_score": 0.017165,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.015792,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.301586
    },
    {
      "title": "Johnson & Johnson stock: $1.30 dividend keeps JNJ in focus before key U.S. data and Jan. 21 earnings",
      "summary": "Johnson & Johnson declared a quarterly dividend of $1.30 per share, payable on March 10, keeping JNJ in investor focus as markets prepare for a data-heavy week. The healthcare stock ended Friday up 0.2%, with attention now shifting to key U.S. economic data releases and the company's fourth-quarter results and webcast on January 21. While the dividend provides income appeal, upcoming economic reports on manufacturing, services, employment, and inflation will significantly influence market direction and demand for income-oriented stocks.",
      "url": "https://ts2.tech/en/johnson-johnson-stock-1-30-dividend-keeps-jnj-in-focus-before-key-u-s-data-and-jan-21-earnings/",
      "source": "ts2.tech",
      "published": "20260105T004201",
      "overall_sentiment_score": 0.017024,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.007559,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.323659
    },
    {
      "title": "2,400 Stocks or 315 Value Picks: Is SCHB or VTV a Better Fit for Your Portfolio?",
      "summary": "This article compares two ETFs, Schwab U.S. Broad Market ETF (SCHB) and Vanguard Value ETF (VTV), to help investors decide which is better for their portfolio. SCHB offers broad market coverage with a tech tilt, while VTV focuses on large-cap value stocks, providing a higher dividend yield. The choice depends on an investor's goals, whether seeking market-wide growth or income from established value companies.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ-N/pressreleases/36877015/2-400-stocks-or-315-value-picks-is-schb-or-vtv-a-better-fit-for-your-portfolio/",
      "source": "The Globe and Mail",
      "published": "20260104T200854",
      "overall_sentiment_score": 0.156692,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.147898,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.583856
    },
    {
      "title": "PDX: An 8.6% Yield, 12% Discount, And Potential Recovery In 2026",
      "summary": "The PIMCO Dynamic Income Strategy Fund (PDX) offers an 8.64% yield and trades at a -12% discount to NAV, which is rare for PIMCO CEFs. PDX is transitioning from an energy-centric portfolio to a multi-sector credit fund, actively reducing its energy exposure to 25%. While high leverage and concentrated energy positions have historically increased volatility, management's de-risking efforts and potential rate cuts could lead to a recovery in 2026.",
      "url": "https://seekingalpha.com/article/4856740-pdx-8-6-percent-yield-12-percent-discount-potential-recovery-in-2026",
      "source": "Seeking Alpha",
      "published": "20260104T131015",
      "overall_sentiment_score": 0.503516,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.506799,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 0.644431
    },
    {
      "title": "The Truth About Intuitive Surgical Inc: Why Everyone Is Betting On Robot Surgeons",
      "summary": "This article analyzes Intuitive Surgical Inc. (ISRG), maker of the da Vinci robotic surgical system, to determine if its high valuation is justified or mere hype. It highlights the company's strong market position due to its \"razor-and-blades\" business model, established user base, and continuous expansion into new procedures, contrasting it with competitors like Medtronic and Johnson & Johnson. The piece concludes that ISRG is a high-conviction play for investors betting on the future of healthcare technology, despite its premium price.",
      "url": "https://www.ad-hoc-news.de/boerse/ueberblick/the-truth-about-intuitive-surgical-inc-why-everyone-is-betting-on-robot/68456701",
      "source": "AD HOC NEWS",
      "published": "20260104T040819",
      "overall_sentiment_score": 0.185491,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.145064,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.72242
    },
    {
      "title": "Pfizer Inc Is On Clearance?! The Wild Truth Behind PFE’s Price Drop",
      "summary": "Pfizer stock (PFE) is currently trading in the mid-$20s, significantly below its pandemic-era highs, leading to debate on Wall Street about whether it's a value buy or a trap. The article discusses PFE's price drop as an opportunity for long-term investors due to future earnings potential and a solid dividend, contrasting it with the views of short-term traders. It analyzes Pfizer's position against competitors and offers a verdict on whether to \"cop or drop\" the stock, emphasizing patience for potential long-term gains.",
      "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pfizer-inc-is-on-clearance-the-wild-truth-behind-pfe-s-price-drop/68455985",
      "source": "AD HOC NEWS",
      "published": "20260103T220922",
      "overall_sentiment_score": 0.140753,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.124146,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.604059
    },
    {
      "title": "Pfizer Inc Is On Clearance?! The Wild Truth Behind PFE’s Price Drop",
      "summary": "Pfizer stock has seen a significant price drop, prompting debate among investors whether it's a value buy or a \"value trap.\" The company's post-vaccine boom market challenges and upcoming drug pipeline are key factors. Despite the bearish sentiment among some, Pfizer offers a solid dividend, appealing to long-term investors seeking a slow-burn recovery play rather than quick gains.",
      "url": "https://www.ad-hoc-news.de/boerse/ueberblick/pfizer-inc-is-on-clearance-the-wild-truth-behind-pfe-s-price-drop/68455985",
      "source": "AD HOC NEWS",
      "published": "20260103T220832",
      "overall_sentiment_score": 0.141032,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.161303,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.649446
    },
    {
      "title": "Johnson & Johnson stock today: JNJ’s $1.30 dividend sets key dates — what investors watch next",
      "summary": "Johnson & Johnson has declared a quarterly cash dividend of $1.30 per share, payable March 10, with the ex-dividend date set for February 24. This announcement comes as JNJ shares closed up 0.2% at $207.35. Investors are now looking forward to the company's fourth-quarter earnings call on January 21 and the broader direction of interest rates.",
      "url": "https://ts2.tech/en/johnson-johnson-stock-today-jnjs-1-30-dividend-sets-key-dates-what-investors-watch-nextnew-york-jan-3-2026-1419-et-market-closed/",
      "source": "ts2.tech",
      "published": "20260103T192046",
      "overall_sentiment_score": 0.175401,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.107811,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026",
      "summary": "Johnson & Johnson announced its Board of Directors has declared a cash dividend of $1.30 per share for the first quarter of 2026. The dividend is payable on March 10, 2026, to shareholders of record as of February 24, 2026, with the ex-dividend date also on February 24, 2026. This announcement highlights the company's commitment to returning value to its shareholders.",
      "url": "https://investingnews.com/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2026/",
      "source": "Investing News Network",
      "published": "20260103T030829",
      "overall_sentiment_score": 0.423966,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.448065,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Caterpillar stock today: CAT jumps 4% after-hours as Dow kicks off 2026 higher — what’s next",
      "summary": "Caterpillar (CAT) shares surged 4.4% in after-hours trading, reaching $598.41, as the Dow started 2026 with a strong rebound. This jump positions Caterpillar as a significant mover for the Dow, with investors anticipating critical U.S. jobs and inflation reports next week, which could impact interest rate expectations. Traders are also looking forward to Caterpillar's upcoming earnings report around January 29th for further insights into its performance and outlook.",
      "url": "https://ts2.tech/en/caterpillar-stock-today-cat-jumps-4-after-hours-as-dow-kicks-off-2026-higher-whats-next/",
      "source": "ts2.tech",
      "published": "20260103T004314",
      "overall_sentiment_score": 0.161803,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.249008,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.609853
    },
    {
      "title": "2,400 Stocks or 315 Value Picks: Is SCHB or VTV a Better Fit for Your Portfolio?",
      "summary": "This article compares two ETFs, Schwab U.S. Broad Market ETF (SCHB) and Vanguard Value ETF (VTV), to help investors decide which is a better fit for their portfolio. SCHB offers broad market coverage with a technology tilt, while VTV focuses on large-cap value stocks, primarily in financials and healthcare, and provides a higher dividend yield. The choice between them depends on an investor's goals, whether seeking comprehensive market representation or higher income from established value companies.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ/pressreleases/36877015/2400-stocks-or-315-value-picks-is-schb-or-vtv-a-better-fit-for-your-portfolio/",
      "source": "The Globe and Mail",
      "published": "20260103T002852",
      "overall_sentiment_score": 0.275421,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.335267,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.62551
    },
    {
      "title": "Johnson & Johnson (NYSE:JNJ) Declares Quarterly Dividend of $1.30",
      "summary": "Johnson & Johnson (NYSE:JNJ) has declared a quarterly dividend of $1.30 per share, payable March 10, 2026, to shareholders of record on February 24, 2026. This dividend, which represents an annualized $5.20 and a yield of approximately 2.5%, marks the 64th consecutive year of dividend increases for the company. Analysts predict Johnson & Johnson's earnings will sufficiently cover the dividend, with a projected future payout ratio of 47.0%.",
      "url": "https://www.marketbeat.com/instant-alerts/johnson-johnson-nysejnj-declares-quarterly-dividend-of-130-2026-01-02/",
      "source": "MarketBeat",
      "published": "20260102T230917",
      "overall_sentiment_score": 0.065572,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.30511,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.966589
    },
    {
      "title": "Johnson & Johnson stock today: JNJ nudges lower after $1.30 dividend as earnings loom",
      "summary": "Johnson & Johnson (JNJ) shares dipped slightly after declaring a $1.30 quarterly dividend, reflecting typical investor reaction to expected payouts from stable companies. The stock's ex-dividend date is February 24, with the dividend payable on March 10. Investors are now focused on the upcoming January 21 earnings call and the broader market's 2026 rate outlook, which influences demand for dividend stocks.",
      "url": "https://ts2.tech/en/johnson-johnson-stock-today-jnj-nudges-lower-after-1-30-dividend-as-earnings-loom/",
      "source": "ts2.tech",
      "published": "20260102T180825",
      "overall_sentiment_score": 0.005472,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.044332,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.303078
    },
    {
      "title": "J&J junks $1.2B eczema therapy while Genmab clears out cancer drug",
      "summary": "Johnson & Johnson has terminated development of its $1.25 billion eczema therapy, JNJ-95475939, after interim analysis of a phase 2b study did not meet efficacy criteria for atopic dermatitis. Meanwhile, Genmab is halting work on its cancer therapy, acasunlimab, despite \"encouraging\" data, to focus on late-stage portfolio opportunities. This decision follows BioNTech's earlier withdrawal from the acasunlimab partnership due to portfolio strategy.",
      "url": "https://www.fiercebiotech.com/biotech/jj-genmab-discard-eczema-cancer-therapies-over-uninspiring-clinical-data",
      "source": "Fierce Biotech",
      "published": "20260102T140746",
      "overall_sentiment_score": 0.063833,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": -0.411843,
      "ticker_sentiment_label": "Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson declares $1.30 per share dividend for Q1 2026",
      "summary": "Johnson & Johnson has announced a quarterly cash dividend of $1.30 per share for the first quarter of 2026, payable on March 10, 2026, to shareholders of record on February 24, 2026. This dividend declaration follows recent strategic acquisitions, including Halda Therapeutics, and FDA approvals for its medical technologies and treatments. The company's recent activities have led to analyst price target increases, reflecting ongoing growth and regulatory advancements.",
      "url": "https://www.investing.com/news/company-news/johnson--johnson-declares-130-per-share-dividend-for-q1-2026-93CH-4427663",
      "source": "Investing.com",
      "published": "20260102T131004",
      "overall_sentiment_score": 0.407811,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.423637,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026",
      "summary": "Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.30 per share for the first quarter of 2026. This dividend is payable on March 10, 2026, to shareholders of record as of February 24, 2026, with the ex-dividend date also being February 24, 2026. The announcement reflects the company's consistent return of value to its shareholders.",
      "url": "https://www.businesswire.com/news/home/20260102290212/en/Johnson-Johnson-Announces-Quarterly-Dividend-for-First-Quarter-2026",
      "source": "Business Wire",
      "published": "20260102T130158",
      "overall_sentiment_score": 0.383271,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.408275,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next",
      "summary": "AbbVie stock closed 2025 down by 0.5% at $228.49 on Wednesday, as U.S. markets shut for the New Year's Day holiday. Investors are now looking ahead to the Federal Reserve's late-January meeting and AbbVie's mid-January dividend record date, with attention on whether the stock can hold above its 50-day moving average and reach its 52-week high in the post-Humira transition period. The drugmaker is focusing on newer immunology medicines like Skyrizi and Rinvoq to offset the decline of Humira.",
      "url": "https://ts2.tech/en/abbvie-stock-ends-2025-lower-as-markets-shut-for-new-year-what-abbv-investors-watch-next/",
      "source": "ts2.tech",
      "published": "20260101T205811",
      "overall_sentiment_score": -0.135411,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.043088,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.623791
    },
    {
      "title": "Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX",
      "summary": "Moody Aldrich Partners LLC decreased its stake in Protagonist Therapeutics, Inc. by 16.1% in the third quarter, selling 27,510 shares and now holding 143,060 shares valued at approximately $9.5 million. Despite this sale, Protagonist Therapeutics remains Moody Aldrich Partners LLC's third-largest holding, and institutional ownership stands at 98.63% due to significant additions by other large funds. Analysts maintain a \"Moderate Buy\" consensus rating with an average target price of $85.08 for the company, which is currently trading near $87.34.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-moody-aldrich-partners-llc-sells-27510-shares-of-protagonist-therapeutics-inc-ptgx-2026-01-01/",
      "source": "MarketBeat",
      "published": "20260101T130913",
      "overall_sentiment_score": 0.209427,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.100049,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.72332
    },
    {
      "title": "Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes",
      "summary": "Pfizer's stock is under scrutiny after a report indicated the company plans to raise U.S. list prices on approximately 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Investors are monitoring for potential policy pushback, especially since January is a key period for annual drug pricing adjustments. The company states its average list-price adjustments are below inflation and are necessary for research and operational costs, while other drugmakers are also adjusting prices, some even cutting them due to government negotiations.",
      "url": "https://ts2.tech/en/pfizer-stock-in-focus-on-new-years-day-after-report-of-2026-u-s-drug-price-hikes/",
      "source": "ts2.tech",
      "published": "20260101T120830",
      "overall_sentiment_score": 0.054656,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.121079,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.60697
    },
    {
      "title": "Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets",
      "summary": "Corcept Therapeutics (CORT) stock plummeted by 50% after the FDA requested more evidence for its relacorilant drug for Cushing’s-related hypertension, leading analysts to cut price targets. While the drug's outlook for hypertension is dim, the FDA has set a July 11, 2026 deadline for relacorilant's review in platinum-resistant ovarian cancer. Investors are now awaiting clarity on potential new trials and the company's next scheduled update in late February.",
      "url": "https://ts2.tech/en/corcept-therapeutics-cort-stock-sinks-after-fda-rebuff-relacorilant-outlook-resets/",
      "source": "ts2.tech",
      "published": "20260101T104500",
      "overall_sentiment_score": -0.270002,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.137765,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.553262
    },
    {
      "title": "The Truth About AbbVie Inc (ABBV): Quiet Pharma Giant, Loud Money Moves",
      "summary": "AbbVie Inc (ABBV) is presented as a quiet pharmaceutical giant known for consistent dividends, strong cash flow, and significant R&D investments, positioning it as a steady compounder rather than a high-volatility stock. The article discusses its appeal to long-term investors seeking income and stability, while also noting risks like patent cliffs and regulatory scrutiny. It compares ABBV to competitors like Johnson & Johnson, highlighting AbbVie's focus on pharma and a stronger dividend growth narrative.",
      "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-abbvie-inc-abbv-quiet-pharma-giant-loud-money-moves/68447435",
      "source": "AD HOC NEWS",
      "published": "20260101T072347",
      "overall_sentiment_score": 0.235141,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.2121,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.735243
    },
    {
      "title": "Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target",
      "summary": "Johnson & Johnson (JNJ) shares closed 2025 slightly up by 0.02% to $206.95, a rare gain as the broader U.S. market declined. This came after the company finalized its $3.05 billion acquisition of Halda Therapeutics, a deal expected to reduce adjusted EPS temporarily. Barclays subsequently raised its price target for JNJ to $217, maintaining an Equal Weight rating, ahead of the company's January results and 2026 outlook presentation.",
      "url": "https://ts2.tech/en/johnson-johnson-stock-ends-2025-steady-as-halda-deal-closes-and-barclays-hikes-target/",
      "source": "ts2.tech",
      "published": "20260101T020818",
      "overall_sentiment_score": -0.15083,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": 0.189773,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.952731
    },
    {
      "title": "BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics",
      "summary": "BioMarin Pharmaceuticals has entered a definitive $4.8 billion all-cash agreement to acquire Amicus Therapeutics. This acquisition is set to significantly expand BioMarin's rare disease portfolio with established Fabry and Pompe franchises, adding late-stage pipeline assets and accelerating revenue growth. The deal, unanimously approved by both boards, is expected to be immediately accretive to BioMarin's non-GAAP diluted EPS in the initial 12 months post-close and strengthen its long-term financial performance.",
      "url": "https://www.pharmexec.com/view/biomarin-reaches-4-8-billion-definitive-agreement-acquire-amicus-therapeutics",
      "source": "Pharmaceutical Executive",
      "published": "20251231T165934",
      "overall_sentiment_score": 0.262091,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.125086,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.566464
    },
    {
      "title": "VTI vs. VTV: How Total Market Exposure Compares to Large-Cap Value Stocks",
      "summary": "This article compares the Vanguard Total Stock Market ETF (VTI) and the Vanguard Value ETF (VTV), highlighting their differences in market exposure, risk, and dividend yield. VTI offers broad diversification across all market caps and sectors, while VTV focuses on large-cap value stocks with a higher dividend yield and lower volatility. The choice between them depends on an investor's goals for diversification, risk tolerance, and income generation.",
      "url": "https://www.fool.com/coverage/etfs/2025/12/31/vti-vs-vtv-how-total-market-exposure-compares-to-large-cap-value-stocks/",
      "source": "The Motley Fool",
      "published": "20251231T154100",
      "overall_sentiment_score": 0.295277,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.31536,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.632122
    },
    {
      "title": "I Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise",
      "summary": "Pfizer shares were flat in premarket trading after a report indicated the company is planning a new round of U.S. list-price increases for 2026 across approximately 80 drugs, including a 15% rise for its COVID vaccine, Comirnaty. This comes as drug pricing gains renewed attention in Washington, with the Trump administration pressing for cost controls. Investors are awaiting Pfizer's Feb. 3 results update and monitoring potential policy responses and payer pushback.",
      "url": "https://ts2.tech/en/pfizer-stock-flat-before-the-bell-as-report-flags-2026-u-s-drug-price-hikes-including-15-comirnaty-rise/",
      "source": "ts2.tech",
      "published": "20251231T140823",
      "overall_sentiment_score": 0.075715,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.091083,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.578492
    },
    {
      "title": "The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On?",
      "summary": "AbbVie Inc. (ABBV) is presented as a \"sleeper stock\" that Gen Z investors might be overlooking, despite its strong dividend yield and defensive characteristics. While not a viral stock like meme shares or AI companies, ABBV offers consistent income and portfolio stability, making it attractive for long-term investors focused on dividend growth rather than quick gains, weighing its established immunology pipeline against the “Humira hangover”.",
      "url": "https://www.ad-hoc-news.de/boerse/ueberblick/the-truth-about-abbvie-inc-is-abbv-the-sleeper-stock-gen-z-is-sleeping/68444886",
      "source": "AD HOC NEWS",
      "published": "20251231T140713",
      "overall_sentiment_score": 0.177338,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.143156,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.632875
    },
    {
      "title": "Here’s What Analysts Think About Halozyme Therapeutics (HALO)",
      "summary": "Halozyme Therapeutics (NASDAQ: HALO) recently received FDA approval for RYBREVANT FASPRO, a subcutaneously administered targeted therapy for EGFR+ mNSCLC, which significantly reduces administration time. However, analysts have mixed opinions, with TD Cowen reaffirming a Buy rating and Goldman Sachs downgrading it to Sell due to concerns about a post-2030 revenue cliff for its Enhanze royalty model. The article also contains significant promotional content for AI-related investment opportunities, suggesting they hold greater promise than HALO.",
      "url": "https://www.insidermonkey.com/blog/heres-what-analysts-think-about-halozyme-therapeutics-halo-1668432/?amp=1",
      "source": "Insider Monkey",
      "published": "20251231T114100",
      "overall_sentiment_score": 0.182655,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.313817,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.716275
    },
    {
      "title": "JP Morgan 2026 Preview: Johnson & Johnson Prepares a Fireside Chat",
      "summary": "Johnson & Johnson is set to host a fireside chat at the upcoming 44th Annual JP Morgan Healthcare Conference, where it may unveil significant acquisition plans for 2026. This follows strategic acquisitions in 2024 and 2025, including Intra-Cellular Therapies for $14.6 billion to bolster its neuroscience portfolio and Ambrx for nearly $2 billion to advance cancer treatment with ADC technology. These moves underscore J&J's focus on expanding its innovative medicine business and addressing critical unmet medical needs.",
      "url": "https://www.pharmexec.com/view/jp-morgan-2026-preview-johnson-johnson-fireside-chat",
      "source": "Pharmaceutical Executive",
      "published": "20251231T111352",
      "overall_sentiment_score": 0.532879,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.542716,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Armstrong Fleming & Moore Inc Purchases 37,650 Shares of T. Rowe Price Blue Chip Growth ETF $TCHP",
      "summary": "Armstrong Fleming & Moore Inc significantly increased its holdings in T. Rowe Price Blue Chip Growth ETF (NYSEARCA:TCHP) by 8.6% in the third quarter, acquiring an additional 37,650 shares. The firm now owns 475,526 shares, making TCHP its largest holding and representing 1.45% of the ETF, valued at $23.24 million. Other institutional investors have also adjusted their positions in TCHP recently, with notable purchases and increases in holdings.",
      "url": "https://www.defenseworld.net/2025/12/31/armstrong-fleming-moore-inc-purchases-37650-shares-of-t-rowe-price-blue-chip-growth-etf-tchp.html",
      "source": "Defense World",
      "published": "20251231T080857",
      "overall_sentiment_score": 0.359043,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.233723,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.645145
    },
    {
      "title": "Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)",
      "summary": "Barclays analyst Matt Miksic reiterated a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target. This comes as the company reported strong Q3 revenues of $23.99 billion and a net profit of $5.15 billion, exceeding last year's figures. Insider sentiment is neutral, though one director recently purchased 1,250 shares.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ-N/pressreleases/36836965/barclays-keeps-their-hold-rating-on-johnson-johnson-jnj/",
      "source": "The Globe and Mail",
      "published": "20251231T080819",
      "overall_sentiment_score": 0.049311,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.010761,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 1.0
    },
    {
      "title": "Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)",
      "summary": "Barclays analyst Matt Miksic has maintained a Hold rating on Johnson & Johnson (JNJ) with a price target of $217.00. This follows previous ratings from other analysts for JNJ, which reported a significant increase in quarterly revenue and net profit. Insider sentiment on the stock is neutral, with one director recently purchasing shares.",
      "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/36836965/barclays-keeps-their-hold-rating-on-johnson-johnson-jnj/",
      "source": "The Globe and Mail",
      "published": "20251231T075050",
      "overall_sentiment_score": 0.009691,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.034155,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 1.0
    },
    {
      "title": "The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast?",
      "summary": "GSK plc (ADR) is presented as a stable pharmaceutical giant focusing on vaccines, respiratory treatments, and oncology, offering steady growth and dividends rather than speculative highs. The article suggests that while it lacks the viral hype of meme stocks or AI, its fundamental business strength and global footprint make it a strong candidate for long-term, fundamentals-first investors looking to diversify their portfolios. Investors should consider its defensive nature, income potential, and the inherent risks of the pharma industry such as lawsuits and patent expirations.",
      "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-gsk-plc-adr-is-wall-street-sleeping-on-this-pharma/68443353",
      "source": "AD HOC NEWS",
      "published": "20251231T053158",
      "overall_sentiment_score": 0.06911,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.061644,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.55832
    },
    {
      "title": "Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead",
      "summary": "Pfizer shares remained flat in after-hours trading as TD Cowen reiterated a \"Hold\" rating due to concerns about weak longer-term trends. Investors are keenly awaiting Pfizer's upcoming results on February 3rd for insights into how the company plans to counter declining COVID-19 product demand and impending patent expirations through new products, acquisitions, and cost reductions. The stock's current low valuation reflects the significant execution risks investors are pricing in, with traders looking for stabilization in COVID-19 product declines, quick scaling of new launches, and effective cost-saving measures.",
      "url": "https://ts2.tech/en/pfizer-stock-flat-after-hours-as-td-cowen-sticks-with-hold-feb-3-results-ahead/",
      "source": "ts2.tech",
      "published": "20251231T010841",
      "overall_sentiment_score": -0.202426,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.235608,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 0.590622
    },
    {
      "title": "JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal",
      "summary": "Johnson & Johnson's shares dipped slightly in after-hours trading following the completion of its $3.05 billion cash acquisition of Halda Therapeutics. This deal introduces Halda's RIPTAC platform and a lead prostate cancer program, HLD-0915, into J&J’s pipeline, with an expected dilution of $0.20 to adjusted EPS for 2025 and 2026. Investors await J&J’s January 21 earnings call for 2026 guidance and details on how this acquisition will impact future earnings and growth.",
      "url": "https://ts2.tech/en/jnj-stock-slips-after-hours-as-johnson-johnson-closes-3-05b-halda-therapeutics-deal/",
      "source": "ts2.tech",
      "published": "20251231T000800",
      "overall_sentiment_score": 0.028497,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.011344,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.349419
    },
    {
      "title": "BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View",
      "summary": "Bank of America has raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650, maintaining a Buy rating, anticipating a biopharma recovery in 2026. The firm believes easing headwinds and a rebound in R&D spending will benefit companies like Thermo Fisher. This outlook also follows Thermo Fisher's recent acquisition of Clario for up to $9.4 billion, aimed at strengthening its clinical trial research business.",
      "url": "https://www.insidermonkey.com/blog/bofa-raises-thermo-fisher-tmo-target-as-biopharma-recovery-comes-into-view-1668403/",
      "source": "Insider Monkey",
      "published": "20251230T230944",
      "overall_sentiment_score": 0.375649,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.328926,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.605327
    },
    {
      "title": "Barclays eleva preço-alvo das ações da Johnson & Johnson para US$ 217",
      "summary": "Barclays increased its price target for Johnson & Johnson (NYSE:JNJ) shares to $217 from $197, maintaining an Equalweight rating, driven by strong growth in its major pharmaceutical franchises like Darzalex and Tremfya. The improved outlook is based on a Q4 revenue growth of approximately 3.4% for key US medicines, surpassing Bloomberg's consensus and Barclays' own estimates. The company also recently acquired Halda Therapeutics for $3.05 billion and received expanded FDA approvals for its TRUFILL n-BCA Embolic System and Akeega for prostate cancer.",
      "url": "https://br.investing.com/news/analyst-ratings/barclays-eleva-precoalvo-das-acoes-da-johnson--johnson-para-us-217-93CH-1786636",
      "source": "Investing.com Brasil - Finanças, Câmbio e Investimentos",
      "published": "20251230T210750",
      "overall_sentiment_score": 0.737515,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.718794,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Completes Acquisition of Halda Therapeutics",
      "summary": "Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company, for $3.05 billion in cash. This acquisition integrates Halda's proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform and its lead prostate cancer therapy, HLD-0915, into J&J's oncology portfolio. The deal expands J&J's pipeline with multiple targeted therapies for various solid tumors and is expected to result in a $0.20 dilution to Adjusted EPS across 2025 and 2026.",
      "url": "https://njbmagazine.com/njb-news-now/johnson-johnson-completes-acquisition-of-halda-therapeutics/",
      "source": "New Jersey Business Magazine",
      "published": "20251230T200828",
      "overall_sentiment_score": 0.249654,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.200607,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Sanofi stock outlook dims as TD Cowen lowers tolebrutinib sales forecast",
      "summary": "TD Cowen has reiterated a Hold rating and €99.00 price target on Sanofi, significantly reducing its 2030 sales estimate for tolebrutinib to €75 million from €1.2 billion after U.S. regulators issued a Complete Response Letter. Despite regulatory setbacks, the firm maintains 2% revenue growth and 4% EPS growth projections for Sanofi during 2025-2032, noting the acquisition of Dynavax Technologies for diversification. The loss of exclusivity for Dupixent is also highlighted as impacting Sanofi’s longer-term prospects and price-to-earnings multiple.",
      "url": "https://www.investing.com/news/analyst-ratings/sanofi-stock-outlook-dims-as-td-cowen-lowers-tolebrutinib-sales-forecast-93CH-4424956",
      "source": "Investing.com",
      "published": "20251230T160920",
      "overall_sentiment_score": -0.112586,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.051803,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.719934
    },
    {
      "title": "Johnson & Johnson Completes $3.05 Billion Halda Therapeutics Acquisition",
      "summary": "Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion in cash, integrating Halda's proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform and its lead prostate cancer therapy, HLD-0915, into J&J's oncology portfolio. This acquisition is expected to dilute J&J's adjusted earnings per share in Q4 2025 and 2026 due to integration costs and employee equity awards. The deal aims to enhance J&J's pipeline with novel targeted therapies for various solid tumors.",
      "url": "https://pulse2.com/johnson-johnson-completes-3-05-billion-halda-therapeutics-acquisition/",
      "source": "Pulse 2.0",
      "published": "20251230T140815",
      "overall_sentiment_score": 0.384848,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.391628,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson awards Minnesota mother $65.5M in talc cancer verdict",
      "summary": "A Minnesota jury has awarded a mother of three $65.5 million in a lawsuit against Johnson & Johnson, claiming the company's talc products exposed her to asbestos and caused cancer in her abdominal lining. This verdict follows other recent judgments against Johnson & Johnson regarding the safety of its talc-based products, with the jury finding the company knowingly marketed contaminated products. The plaintiff, diagnosed with peritoneal mesothelioma, used Johnson & Johnson's baby powder throughout her childhood.",
      "url": "https://topclassactions.com/lawsuit-settlements/lawsuit-news/johnson-johnson-awards-minnesota-mother-65-5m-in-talc-cancer-verdict",
      "source": "Class Action Lawsuits",
      "published": "20251230T140812",
      "overall_sentiment_score": -0.717769,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment_score": -0.732259,
      "ticker_sentiment_label": "Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target",
      "summary": "Johnson & Johnson (JNJ) shares slipped slightly in midday trading after the company announced the closing of its $3.05 billion acquisition of Halda Therapeutics, a deal expected to reduce adjusted EPS by approximately $0.20 split between 2025 and 2026. Barclays raised its price target for JNJ to $217 while maintaining an \"Equal Weight\" rating, citing potential upside to Q4 consensus expectations from key drug sales. The acquisition adds a new platform for oral, targeted cancer medicines and a clinical-stage prostate cancer program to J&J's pipeline.",
      "url": "https://ts2.tech/en/johnson-johnson-stock-today-jnj-slips-after-3-05b-halda-cancer-deal-closes-barclays-lifts-target/",
      "source": "ts2.tech",
      "published": "20251230T124400",
      "overall_sentiment_score": 0.042897,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.029617,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.327802
    }
  ]
}